Mixed results with modulation of TH-17 cells in human autoimmune diseases
Mixed results with modulation of TH-17 cells in human autoimmune diseases
复制标题
DOI：
10.1038/ni.1803
复制
发表时间：
2010-01-01
影响因子：
30.5
通讯作者：
Steinman, Lawrence
中科院分区：
文献类型：
--
作者：
Steinman, Lawrence
临床试验的结果为阐明特定细胞因子在人类疾病发病机制中的作用提供了最令人信服的数据。由于各种实际原因，免疫学界将其大部分研究时间和资金花在了模型系统的研究上，主要是小鼠。从这个角度来看，我讨论了临床试验的结果，这些试验评估了阻断产生白细胞介素17的CD4(+)T细胞的分化和/或功能对人类自身免疫性疾病的影响，并将更有限的注意力放在从动物模型中证实临床前研究。到目前为止，这些在人体试验中的结果好坏参半，在牛皮癣和克罗恩病方面取得了显著的成功，但在复发-缓解型多发性硬化症方面取得了负面结果。
The outcomes of clinical trials provide the most convincing data to clarify the role of particular cytokines in the pathogenesis of human diseases. The immunology community, for a variety of practical reasons, spends most of its research time and funds on studies in model systems, mainly mice. In this perspective I discuss results of clinical trials assessing the effect of blocking the differentiation and/or function of interleukin-17-producing CD4(+) T cells on human autoimmune disease, and devote more limited attention to corroborating preclinical studies from animal models. Thus far, these outcomes in human trials have been mixed, with notable success in psoriasis and Crohn's disease but a negative result in relapsing-remitting multiple sclerosis.